Stocktoria
Entera Bio Ltd. ENTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-06-28
Chart by TradingView
2/9
Piotroski F — financial health
-20.27
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $42,000 | $181,000 | $0 | $134,000 | $571,000 |
| Gross profit | $0 | $9,000 | $0 | $33,000 | $198,000 |
| Operating income | -$11.5M | -$9.6M | -$8.9M | -$13.0M | -$12.2M |
| Net income | -$11.4M | -$9.5M | -$8.9M | -$13.1M | -$12.2M |
| Operating cash flow | -$7.4M | -$6.8M | -$7.3M | -$12.5M | -$9.1M |
| Free cash flow | -$7.5M | -$6.8M | -$7.3M | -$12.5M | -$9.1M |
| Total assets | $16.0M | $9.4M | $11.8M | $13.1M | $26.0M |
| Total liabilities | $2.9M | $1.3M | $1.4M | $1.4M | $3.4M |
| Shareholders' equity | $13.1M | $8.1M | $10.4M | $11.8M | $22.6M |
| Ratios | |||||
| Gross margin | 0.0% | 5.0% | — | 24.6% | 34.7% |
| Operating margin | -27450.0% | -5295.6% | — | -9714.2% | -2139.6% |
| Net margin | -27235.7% | -5271.3% | — | -9754.5% | -2134.3% |
| FCF margin | -17802.4% | -3768.5% | — | -9362.7% | -1590.2% |
| Return on assets | -71.5% | -101.6% | -75.6% | -99.6% | -46.9% |
| Return on equity | -87.3% | -118.1% | -85.6% | -111.2% | -54.0% |
| Current ratio | 6.94 | 7.63 | 10.32 | 9.58 | 8.01 |
| Revenue growth | -76.8% | — | -100.0% | -76.5% | 56.4% |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -20.27 (distress)
- Working capital / assets 0.819
- Retained earnings / assets -7.839
- EBIT / assets -0.721
- Equity / liabilities 4.53
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001638097 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.